Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Bone Marrow Transplantation (22)
Leukemia (8)
Nature Medicine (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (21)
Correspondence (7)
Amendments and Corrections (1)
Reviews (1)
Special Features (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Cancer
Diseases
Genetics
Health care
Immunology
Medical research
Oncology
Stem cells

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–31 of 31 results

Advanced filters: Author: P Kebriaei Clear advanced filters

Autologous T cell therapy for MAGE-A4⁺ solid cancers in HLA-A*02⁺ patients: a phase 1 trial

In a phase 1 dose-escalation trial in patients with nine different types of solid tumors, MAGE-A4-specific T cells had an acceptable safety profile and exhibited an encouraging overall response rate in patients with synovial sarcoma.

David S. Hong
Brian A. Van Tine
Marcus O. Butler
ResearchOpen Access09 Jan 2023
Nature Medicine

Volume: 29, P: 104-114
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

Rasha W. Al-Ali
Gege Gui
Christopher S. Hourigan
CorrespondenceOpen Access24 Nov 2025
Bone Marrow Transplantation

Volume: 61, P: 222-224
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts

G S Hobbs
A Hamdi
P Kebriaei
Research26 Jan 2015
Bone Marrow Transplantation

Volume: 50, P: 493-498
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

Paolo Strati
Andrew P. Jallouk
Sattva S. Neelapu
Research20 Sept 2022
Leukemia

Volume: 36, P: 2669-2677
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Antonio M. Jimenez Jimenez
Marcos De Lima
Daniel Weisdorf
Research28 Sept 2021
Bone Marrow Transplantation

Volume: 56, P: 3068-3077
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

Mahmoud R. Gaballa
Junsheng Ma
Muzaffar H. Qazilbash
Research06 May 2022
Bone Marrow Transplantation

Volume: 57, P: 1142-1149
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

S O Ciurea
R Saliba
J Gajewski
Research10 Aug 2009
Bone Marrow Transplantation

Volume: 45, P: 429-436
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia

P Kebriaei
R M Saliba
I F Khouri
Research26 Jun 2006
Bone Marrow Transplantation

Volume: 38, P: 203-209
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma

M H Qazilbash
R M Saliba
S A Giralt
Research29 Jan 2007
Bone Marrow Transplantation

Volume: 39, P: 279-283
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL

P Kebriaei
T Madden
B S Andersson
Research25 Jun 2012
Bone Marrow Transplantation

Volume: 48, P: 26-31
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

U Popat
M J de Lima
S A Giralt
Research21 Mar 2011
Bone Marrow Transplantation

Volume: 47, P: 212-216
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

P Kebriaei
J Kline
K van Besien
Research04 Apr 2005
Bone Marrow Transplantation

Volume: 35, P: 965-970
Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia

L M Poon
R Bassett Jr
P Kebriaei
Research22 Oct 2012
Bone Marrow Transplantation

Volume: 48, P: 666-670
Improved detection of sinusoidal obstructive syndrome using pediatric–AYA diagnostic criteria and severity grading

D. Ragoonanan
S. J. Khazal
F. P. Tambaro
Research14 Jul 2020
Bone Marrow Transplantation

Volume: 56, P: 175-184
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

L De Padua Silva
M de Lima
F Ravandi
Research19 Jan 2009
Bone Marrow Transplantation

Volume: 43, P: 839-843
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

P Kongtim
K Adekola
S O Ciurea
Correspondence12 Apr 2017
Leukemia

Volume: 31, P: 1654-1657
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

I Aldoss
R C Bargou
S J Forman
Reviews28 Dec 2016
Leukemia

Volume: 31, P: 777-787
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

Y Chen
H Kantarjian
F Ravandi
Research08 Nov 2012
Leukemia

Volume: 27, P: 836-842
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

V Bachanova
D I Marks
D J Weisdorf
Research30 Aug 2013
Leukemia

Volume: 28, P: 658-665
Is there an expiration date for a cord blood unit in storage?

S Parmar
M de Lima
R Champlin
Correspondence23 Apr 2014
Bone Marrow Transplantation

Volume: 49, P: 1109-1112
Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes

J E Brammer
R M Saliba
P Kebriaei
Research12 Sept 2016
Bone Marrow Transplantation

Volume: 52, P: 20-27
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

B Oran
S Giralt
M de Lima
Correspondence05 Jul 2007
Leukemia

Volume: 21, P: 2540-2544
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation

M Konopleva
C B Benton
R Champlin
Research13 Apr 2015
Bone Marrow Transplantation

Volume: 50, P: 939-946
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

M de Lima
R E Champlin
S Giralt
Research08 Nov 2007
Leukemia

Volume: 22, P: 258-264
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

N Shah
P F Thall
M H Qazilbash
Correspondence27 Feb 2015
Leukemia

Volume: 29, P: 1945-1948
Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation

A Varma
R M Saliba
U Popat
Correspondence07 Mar 2016
Bone Marrow Transplantation

Volume: 51, P: 999-1001
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

B S Andersson
P F Thall
R E Champlin
Research19 Dec 2016
Bone Marrow Transplantation

Volume: 52, P: 580-587
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Antonio M. Jimenez Jimenez
Marcos De Lima
Daniel Weisdorf
Amendments and Corrections16 Mar 2022
Bone Marrow Transplantation

Volume: 57, P: 852
Umbilical cord blood graft engineering: challenges and opportunities

P A Thompson
K Rezvani
E J Shpall
Research03 Jun 2015
Bone Marrow Transplantation

Volume: 50, P: S55-S62
Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury

N Oliver
T Luong
A Abudayyeh
Special Features09 May 2016
Bone Marrow Transplantation

Volume: 51, P: 1301-1304
Alopecia areata after HLA-identical BMT from an affected, sibling donor

S Nadeem
S Hymes
M Duvic
Correspondence20 Jan 2014
Bone Marrow Transplantation

Volume: 49, P: 592-594

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

Search

Autologous T cell therapy for MAGE-A4⁺ solid cancers in HLA-A*02⁺ patients: a phase 1 trial

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts

Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia

Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma

Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia

Improved detection of sinusoidal obstructive syndrome using pediatric–AYA diagnostic criteria and severity grading

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Is there an expiration date for a cord blood unit in storage?

Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Umbilical cord blood graft engineering: challenges and opportunities

Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury

Alopecia areata after HLA-identical BMT from an affected, sibling donor

Search

Quick links